PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. - Wikidata - awgldk - TriplyDB

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

http://www.wikidata.org/entity/Q37726682

about

Aptamers: A Feasible Technology in Cancer Immunotherapy Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Molecular profiling in the treatment of colorectal cancer: focus on regorafenib Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy New developments in the management of advanced melanoma - role of pembrolizumab The Promise of Preventive Cancer Vaccines Acquired and intrinsic resistance in cancer immunotherapy Overcoming T cell exhaustion in infection and cancer To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations From mice to humans: developments in cancer immunoediting POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Role of TIM-3 in ovarian cancer.Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy.B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.Adoptive cell transfer as personalized immunotherapy for human cancer.Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.Inhibitory Receptors Beyond T Cell Exhaustion.Consensus nomenclature for CD8(+) T cell phenotypes in cancer Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8(+) T cells.MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

P2860

Q26740303-1E836936-6BEC-404C-B6E4-9F7965BC52FB Q26744527-2EE2AEC0-865E-422F-8D9E-3CBE4BACAC43 Q26746099-3F943543-8781-499D-8906-678080926C35 Q26775034-9E03DAA7-C75B-48A8-87D6-B0F1A24512C6 Q26778296-C130F43E-4762-4A2E-A802-FDFC569737D2 Q26779184-D18FE683-52E5-419A-A921-C590464E5B35 Q26781931-1DB835D0-40BE-4F0A-8CAD-9E2AAEA6FD2A Q26783742-032CBB91-819F-4587-BB69-FAF42E6E93F4 Q26827701-6A3EC4E1-5BFC-400C-B4FA-313945FE7928 Q26829885-6BA40C0F-67EF-4272-B24C-F86D1C6799D7 Q27008423-C1F5F8D9-7555-4FBC-B921-E68C688A985D Q27853210-E2EE1D1B-40B6-4DA7-B5E4-1758CEE3CE7B Q27853339-9D8B7121-E6AD-4ECF-8E60-127EF8B21378 Q28075712-9352990B-AAF2-4DC6-AA6E-F14731938B53 Q28088304-1F0005CC-162A-4D81-AD7D-BD8D4D8D7DD5 Q28260529-E35B15CA-C063-4C03-969C-1FD8E5EB3462 Q29617771-0C2A1160-7162-4E24-9FA6-53BAA683C5D1 Q30235023-77ABE007-9094-4CD1-8279-D8565ACD1BE6 Q30830664-58FDE2FF-330B-45E6-8971-EF2EE93A625A Q30832820-4199DF39-73FB-41D9-B74C-78E9A562C107 Q33572965-B0A43BAB-0ECA-4BE9-98AF-E86E9F51C635 Q33632113-1E9F9ED0-32C2-49EB-BED3-25B03F26A534 Q33668084-5929D1E3-E8EC-498C-9857-16BC7C52A734 Q33718731-CCCAEAF9-B5BD-4D68-B274-AA5B3965CCC3 Q33816848-02F41033-15B6-46C8-9989-F708C7E180AB Q33839273-45E8BAA9-0503-4C27-8C7F-4D63646C4D10 Q34043643-A9B65B08-E525-401D-80D8-70E24ED182C7 Q34458339-C369EEFD-7661-4930-AE6A-442A82466926 Q34502985-CC4C0054-FDDA-4594-BC53-76AEBF9F7269 Q34517192-5D891B3B-41A7-40BE-8560-AC95B805E7FE Q34749303-5B1B5CEB-A452-44EB-8A7D-6F5911151A56 Q35507524-0E5165F5-2D76-4084-BB18-EDFC2E01201F Q35639002-33CD3CEB-50B3-4AAA-B944-91460CAF873B Q35677962-9631FC0F-89DC-46D6-B13B-0B05D2BA01FE Q35751259-DB5DDAF9-CBE2-4CFB-BD0D-9490B4C1170B Q35783318-D272739C-1CFA-423B-989F-D748D4A94962 Q35798822-639534BE-4137-44C4-9307-71F43B2CCA68 Q35798858-6A067EA7-1AC0-4223-9ADE-3DF3F4F897DB Q35898801-D4ACD219-86AC-456A-91B7-FB2FA0CFF692 Q35908369-7FF13FDD-AB79-495E-8589-9F6477DDB6CF

P2860

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

http://www.wikidata.org/entity/Q37726682

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PD-1 identifies the patient-sp ...... ire infiltrating human tumors.

@en

PD-1 identifies the patient-sp ...... ire infiltrating human tumors.

@nl

type

label

PD-1 identifies the patient-sp ...... ire infiltrating human tumors.

@en

PD-1 identifies the patient-sp ...... ire infiltrating human tumors.

@nl

prefLabel

PD-1 identifies the patient-sp ...... ire infiltrating human tumors.

@en

PD-1 identifies the patient-sp ...... ire infiltrating human tumors.

@nl

P1433

Q37726682-6B4C2674-2C14-4721-B347-8EC35A2BA149

P1476

Q37726682-5075265A-B1EA-4D0C-8BAD-8CB5AD78780A

P2093

Q37726682-069C4058-920B-4A68-9B74-4835C10CBD02

Q37726682-0A8C5837-35CD-40DF-8624-5CF3B797992F

Q37726682-337103DF-109C-453A-9639-F783A8F37116

Q37726682-6DDFE391-6F75-4F45-A5E5-79FE71156F84

Q37726682-7F5A8E6D-01CF-4E31-A8EA-CA25051208D8

Q37726682-9AD657CD-971F-4B46-BDB8-6F7C4578583D

Q37726682-9D0008D1-C57C-4215-9C8B-2FBB2557BF38

Q37726682-A54C4273-1F18-4DE7-BED0-86B6C66721F1

Q37726682-B70F38BC-25AA-4B3A-8D26-6EFC56077059

Q37726682-DBBD08FA-A4FB-4E84-9BB4-7C13EB2BD774

P2860

Q37726682-054EEF5C-2376-42BA-AF44-2E40F6209A7D

Q37726682-07956935-CE49-41F3-95CA-9B6F05EA3F0C

Q37726682-0B3DEEEC-1409-48CB-BAEA-DD20419686DA

Q37726682-0C8172B9-EBAB-4276-A0B3-55518D7D555F

Q37726682-13FCE421-5ED8-4933-8EEB-22130F5B534F

Q37726682-15211E86-E834-41EA-AAA6-4AAF22936C82

Q37726682-189A1BB4-35CE-4DF0-A693-AFEDB4D0D3ED

Q37726682-1B518533-9297-4F48-9756-9673FCBC81D2

Q37726682-1F562B9C-665A-441C-9958-102C11116A89

Q37726682-2481AD1F-B6B3-491E-9244-7F42FAAB42FA

P304

Q37726682-81B39DDA-7849-433D-8188-1625867F369E

P31

Q37726682-D9206D9F-D3A0-4134-A335-5784E033AA1D

P356

Q37726682-A1CE1BC9-468F-425F-B16E-1D43FC0B3B7A

P407

Q37726682-A2BF76D2-E0B1-43E2-8BE3-71C385D81E0A

P433

Q37726682-A56E2F2F-C166-4F79-84C6-8E23AC5DCBA8

P478

Q37726682-A9160CEA-A863-4F81-B0E4-B3EC33F0FDDD

P50

Q37726682-6F246D75-9007-4CAC-9515-3B91871A7CFA

P577

Q37726682-0DF380A2-16C9-4F33-B89D-87525759FB62

P698

Q37726682-4C0ED888-C4C4-4F06-A26A-7B15F2D6AAA5

P921

Q37726682-31D98561-1C54-49F0-8C13-9E98A7F294C9

P932

Q37726682-BFCAE4DB-08AF-49AC-99B5-B6C910B942D5

P356

P1433

Journal of Clinical Investigation

P1476

PD-1 identifies the patient-sp ...... ire infiltrating human tumors.

@en

P2093

Arnold Mixon

http://www.w3.org/2001/XMLSchema#string

Daniel C Douek

http://www.w3.org/2001/XMLSchema#string

Eric Tran

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

John R Wunderlich

http://www.w3.org/2001/XMLSchema#string

Jorge R Almeida

http://www.w3.org/2001/XMLSchema#string

Ken-Ichi Hanada

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Paul F Robbins

http://www.w3.org/2001/XMLSchema#string

Sam Darko

http://www.w3.org/2001/XMLSchema#string

P2860

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Viral immune evasion due to persistence of activated T cells without effector function

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Database of T cell-defined human tumor antigens: the 2013 update

P304

2246-2259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI73639

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24667641

http://www.w3.org/2001/XMLSchema#string

P921

P932

4001555

http://www.w3.org/2001/XMLSchema#string